109 related articles for article (PubMed ID: 38872577)
1. MEK inhibitors and DA-Raf, a dominant-negative antagonist of the Ras-ERK pathway, prevent the migration and invasion of KRAS-mutant cancer cells.
Matsuda A; Masuzawa R; Takahashi K; Takano K; Endo T
Cytoskeleton (Hoboken); 2024 Jun; ():. PubMed ID: 38872577
[TBL] [Abstract][Full Text] [Related]
2. DA-Raf, a dominant-negative antagonist of the Ras-ERK pathway, is a putative tumor suppressor.
Kanno E; Kawasaki O; Takahashi K; Takano K; Endo T
Exp Cell Res; 2018 Jan; 362(1):111-120. PubMed ID: 29129563
[TBL] [Abstract][Full Text] [Related]
3. Dominant-negative antagonists of the Ras-ERK pathway: DA-Raf and its related proteins generated by alternative splicing of Raf.
Endo T
Exp Cell Res; 2020 Feb; 387(2):111775. PubMed ID: 31843497
[TBL] [Abstract][Full Text] [Related]
4. DA-Raf, a dominant-negative regulator of the Ras-ERK pathway, is essential for skeletal myocyte differentiation including myoblast fusion and apoptosis.
Takahashi K; Itakura E; Takano K; Endo T
Exp Cell Res; 2019 Mar; 376(2):168-180. PubMed ID: 30742807
[TBL] [Abstract][Full Text] [Related]
5. DA-Raf-Mediated Suppression of the Ras--ERK Pathway Is Essential for TGF-β1-Induced Epithelial-Mesenchymal Transition in Alveolar Epithelial Type 2 Cells.
Watanabe-Takano H; Takano K; Hatano M; Tokuhisa T; Endo T
PLoS One; 2015; 10(5):e0127888. PubMed ID: 25996975
[TBL] [Abstract][Full Text] [Related]
6. DA-Raf and the MEK inhibitor trametinib reverse skeletal myocyte differentiation inhibition or muscle atrophy caused by myostatin and GDF11 through the non-Smad Ras-ERK pathway.
Masuzawa R; Takahashi K; Takano K; Nishino I; Sakai T; Endo T
J Biochem; 2022 Jan; 171(1):109-122. PubMed ID: 34676394
[TBL] [Abstract][Full Text] [Related]
7. DA-Raf1, a competent intrinsic dominant-negative antagonist of the Ras-ERK pathway, is required for myogenic differentiation.
Yokoyama T; Takano K; Yoshida A; Katada F; Sun P; Takenawa T; Andoh T; Endo T
J Cell Biol; 2007 Jun; 177(5):781-93. PubMed ID: 17535970
[TBL] [Abstract][Full Text] [Related]
8. Onco-immunomodulatory properties of pharmacological interference with RAS-RAF-MEK-ERK pathway hyperactivation.
Avery TY; Köhler N; Zeiser R; Brummer T; Ruess DA
Front Oncol; 2022; 12():931774. PubMed ID: 35965494
[TBL] [Abstract][Full Text] [Related]
9. An oncogenic mutant of RHEB, RHEB Y35N, exhibits an altered interaction with BRAF resulting in cancer transformation.
Heard JJ; Phung I; Potes MI; Tamanoi F
BMC Cancer; 2018 Jan; 18(1):69. PubMed ID: 29320991
[TBL] [Abstract][Full Text] [Related]
10. Roles of the Raf/MEK/ERK pathway in cell growth, malignant transformation and drug resistance.
McCubrey JA; Steelman LS; Chappell WH; Abrams SL; Wong EW; Chang F; Lehmann B; Terrian DM; Milella M; Tafuri A; Stivala F; Libra M; Basecke J; Evangelisti C; Martelli AM; Franklin RA
Biochim Biophys Acta; 2007 Aug; 1773(8):1263-84. PubMed ID: 17126425
[TBL] [Abstract][Full Text] [Related]
11. Relationships among
Wan XB; Wang AQ; Cao J; Dong ZC; Li N; Yang S; Sun MM; Li Z; Luo SX
World J Gastroenterol; 2019 Feb; 25(7):808-823. PubMed ID: 30809081
[TBL] [Abstract][Full Text] [Related]
12. Protein kinase C alpha trigger Ras and Raf-independent MEK/ERK activation for TPA-induced growth inhibition of human hepatoma cell HepG2.
Wen-Sheng W
Cancer Lett; 2006 Jul; 239(1):27-35. PubMed ID: 16169661
[TBL] [Abstract][Full Text] [Related]
13. Protein Kinase CK2α Maintains Extracellular Signal-regulated Kinase (ERK) Activity in a CK2α Kinase-independent Manner to Promote Resistance to Inhibitors of RAF and MEK but Not ERK in BRAF Mutant Melanoma.
Zhou B; Ritt DA; Morrison DK; Der CJ; Cox AD
J Biol Chem; 2016 Aug; 291(34):17804-15. PubMed ID: 27226552
[TBL] [Abstract][Full Text] [Related]
14. SOS1 and KSR1 modulate MEK inhibitor responsiveness to target resistant cell populations based on PI3K and KRAS mutation status.
Daley BR; Vieira HM; Rao C; Hughes JM; Beckley ZM; Huisman DH; Chatterjee D; Sealover NE; Cox K; Askew JW; Svoboda RA; Fisher KW; Lewis RE; Kortum RL
Proc Natl Acad Sci U S A; 2023 Nov; 120(47):e2313137120. PubMed ID: 37972068
[TBL] [Abstract][Full Text] [Related]
15. Bromodomain containing protein represses the Ras/Raf/MEK/ERK pathway to attenuate human hepatoma cell proliferation during HCV infection.
Zhang Q; Wei L; Yang H; Yang W; Yang Q; Zhang Z; Wu K; Wu J
Cancer Lett; 2016 Feb; 371(1):107-16. PubMed ID: 26620707
[TBL] [Abstract][Full Text] [Related]
16. Pharmacologic inhibition of RAF-->MEK-->ERK signaling elicits pancreatic cancer cell cycle arrest through induced expression of p27Kip1.
Gysin S; Lee SH; Dean NM; McMahon M
Cancer Res; 2005 Jun; 65(11):4870-80. PubMed ID: 15930308
[TBL] [Abstract][Full Text] [Related]
17. Syndecan-1 suppresses cell growth and migration via blocking JAK1/STAT3 and Ras/Raf/MEK/ERK pathways in human colorectal carcinoma cells.
Wang S; Zhang X; Wang G; Cao B; Yang H; Jin L; Cui M; Mao Y
BMC Cancer; 2019 Nov; 19(1):1160. PubMed ID: 31783811
[TBL] [Abstract][Full Text] [Related]
18. Targeting RAS-RAF-MEK-ERK signaling pathway in human cancer: Current status in clinical trials.
Song Y; Bi Z; Liu Y; Qin F; Wei Y; Wei X
Genes Dis; 2023 Jan; 10(1):76-88. PubMed ID: 37013062
[TBL] [Abstract][Full Text] [Related]
19. MicroRNA‑143‑3p suppresses cell growth and invasion in laryngeal squamous cell carcinoma via targeting the k‑Ras/Raf/MEK/ERK signaling pathway.
Zhang F; Cao H
Int J Oncol; 2019 Feb; 54(2):689-701. PubMed ID: 30535502
[TBL] [Abstract][Full Text] [Related]
20. Mutational analysis of the RAS/RAF/MEK/ERK signaling pathway in 260 Han Chinese patients with cervical carcinoma.
Zou Y; Liu FY; Wu J; Wan L; Fang SF; Zhang ZY; Luo Y; Chen MH; Huang MZ; He M; Huang OP
Oncol Lett; 2017 Aug; 14(2):2427-2431. PubMed ID: 28781678
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
